TNFSF10 and cancer: Collectively, these data demonstrated that dinaciclib is potent for sensitizing in vivo TRAIL response in cancers and its combination with EV-T can trigger strikingly enhanced apoptosis induction resulting in complete eradication of subcutaneous TRAIL-resistant A549 tumor growth.